Stephanie Tagliatela
Co-Founder & Chief Scientific Officer Encoded Therapeutics
Stephanie Tagliatela is co-founder, chief scientific officer and member of the board of directors at Encoded Therapeutics. She is passionate about building and aligning cross-functional teams to move gene therapy beyond the technical limitations that exist today. Stephanie has helped shape Encoded’s sequencing-based technologies and apply them across a range of high impact disease areas. She has been named by Business Insider as one of the 30 biotech leaders under 40 searching for breakthrough treatments and shaping the future of medicine. Prior to Encoded, Stephanie conducted doctoral research in Molecular and Cellular Neuroscience at MIT. She received her B.A. in Biological Sciences from Mount Holyoke College.
Seminars
- Demonstrating durable SCN1A upregulation using AAV9-based gene regulation in clinical development
- Translating cell-selective targeting of inhibitory neurons into disease-modifying potential in Dravet syndrome
- Optimizing precision gene control strategies to improve safety and efficacy in CNS ion channel disorders
